Divi’s Labs Vying For No. 2 Spot Among India’s Generics-Dominated Pharma Stocks
Capsules are laid out for inspection on the production line of a drug factory. (Photographer: Tomohiro Ohsumi/Bloomberg)

Divi’s Labs Vying For No. 2 Spot Among India’s Generics-Dominated Pharma Stocks

When the U.S. drug regulator effectively barred exports from Divi’s Laboratories Ltd.’s biggest facility in Visakhapatnam in March 2017, the maker of pharma raw materials wiped off half of its valu...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.